1. Use of belimumab in treating patients with systemic lupus erythematosus: a single-center, real-world retrospective study
- Author
-
Zhaohui Su, Chunyi Zhang, Congcong Gao, Chaoying Li, Ruxv Li, and Zhaohui Zheng
- Subjects
SLE ,Belimumab ,DORIS remission ,LLDAS ,Complete remission ,Partial remission ,Diseases of the musculoskeletal system ,RC925-935 - Abstract
Abstract Objective To investigate the efficacy and safety of belimumab in the treatment of systemic lupus erythematosus (SLE) in a real-world setting and provide a valuable reference for clinical treatment. Methods In this retrospective study, 101 patients with SLE who came to our hospital from March 2020 to September 2022, 56 of whom with lupus nephritis (LN), were selected. All patients received belimumab in combination with standard of care(SoC)therapy regimen for more than 52 weeks and their clinical/laboratory data, assessment of disease activity, glucocorticoids dosage and occurrence of adverse events were recorded. Lupus Low Disease Activity State (LLDAS) and DORIS remission as a primary goal in the treatment of SLE. The groups were classified according to the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2 K): SLEDAI-2 K
- Published
- 2024
- Full Text
- View/download PDF